Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer

Urology

Volumn 51, Issue 4, 1998, Pages 645-649

  Türkeri, Levent N ^a,b   Erton, Mustafa L ^a   Çevik, Ibrahim ^a   Akdaş, Atif ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR DENSITY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; URINARY BLADDER NEOPLASMS;

EID: 2542507626     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00648-1     Document Type: Article

References (12)

1. Heney NM: Natural history of superficial bladder cancer: prognostic features and long-term disease course. Urol Clin North Am 19: 429-433, 1992.
2. Badalament RA, Ortolano V, and Burgers JK: Recurrent or aggressive bladder cancer: indications for adjuvant intravesical therapy. Urol Clin North Am 19: 485-498, 1992.
3. Messing EM, and Murphy-Brooks N: Recovery of epidermal growth factor in voided urine of patients with bladder cancer. Urology 44: 502-506, 1994.
4. Neal DE, Sharples L, Smith K, Fennely J, Hall RR, and Harris AL: The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65: 1619-1625, 1990.
5. Neal DE, and Mellon K: Epidermal growth factor receptor and bladder cancer: a review. Urol Int 48: 365-371, 1992.
6. American Joint Committee on Cancer: Manual for Staging Cancer 1983. Philadelphia, JB Lippincott, 1983, p 171.
7. Mostofi FK, Sobin LH, and Torlini H: Histological typing of urinary bladder tumors. International Histological Classification of Tumors, No. 10. Geneva, World Health Organization, 1973.
8. Messing EM: Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 50: 2530-2537, 1990.
9. Berger MS, Greenfield C, Gullick WJ, Haley J, Downward J, Neal DE, Harris AL, and Waterfield MD: Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer 56: 533-537, 1987.
10. Theodorescu D, Cornil I, Sheehan C, Man MS, and Kerbel RS: Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. Cancer Res 51: 4486-4491, 1991.
11. Türkeri LN, Sakr WA, Wykes SM, Grignon DJ, Pontes JE, and Macosca JA: Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign, premalignant, and malignant prostate tissue. Prostate 25: 199-205, 1994.
12. Gleave M, Hsieh JT, Gao C, von Eschenbach AC, and Chung LWK: Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51: 3753-3761, 1991.